Home / Market News / $ACAD

$ACAD news and market catalysts

The 35 most recent market catalysts affecting $ACAD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

35 catalysts 4 high impact 22 bullish 8 bearish Pharmaceuticals
Nov 18, 2026 Corporate Catalyst Bearish Impact 55
Oppenheimer Adjusts Acadia Pharmaceuticals Price Target to $21
Oppenheimer, a prominent analyst firm, adjusted its price target for Acadia Pharmaceuticals (ACAD) down to $21 from $23. This change, while maintaining a 'Perform' rating, indicate…
Nov 16, 2026 Corporate Catalyst Bullish Impact 65
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX in Japan
Acadia Pharmaceuticals has secured an exclusive distribution agreement with KYORIN Pharmaceutical for its Rett syndrome treatment, DAYBUE® STIX, in Japan. This is a significant ste…
Nov 13, 2026 Corporate Catalyst Bullish Impact 55
Analyst Actions Regarding Acadia Pharmaceuticals
On November 13, 2026, an analyst lowered the price target for Acadia Pharmaceuticals to $24.00 per share. Despite this reduction, the stock's rating was maintained at 'Equal-Weight…
Nov 13, 2026 Corporate Catalyst Bearish Impact 65
Morgan Stanley Lowers Price Target for ACADIA Pharmaceuticals Inc.
Morgan Stanley, a prominent investment bank, has reduced its price target for ACADIA Pharmaceuticals Inc. from $28 to $24. This action indicates a revised, less favorable outlook o…
Nov 12, 2026 Corporate Catalyst Bearish Impact 75
Analysis of Acadia Pharmaceuticals' Cash Flow and Profitability
Acadia Pharmaceuticals reported a net profit of $362.2 million for the twelve months ending September 2026, but only generated $82 million in free cash flow. This discrepancy is hi…
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
Acadia Pharmaceuticals to Present Remlifanserin Data at 2026 CTAD Conference
Acadia Pharmaceuticals announced it will present Phase 2 data from its RADIANT clinical trial for remlifanserin at the 2026 CTAD conference. This is a forward-looking disclosure, s…
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Raises Acadia Healthcare Price Target to $41
Guggenheim has raised its price target for Acadia Healthcare Company, Inc. (ACAD) from $39 to $41. This adjustment reflects a slightly improved valuation perspective from the analy…
Nov 6, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Markets Raises Price Target on Acadia Pharmaceuticals
RBC Capital Markets' decision to raise Acadia Pharmaceuticals' price target from $31 to $41, alongside maintaining an Outperform rating, is a direct consequence of the company's re…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $36
RBC Capital Markets raised its price target on Acadia Pharmaceuticals (ACAD) to $38 from $36, while reiterating an 'Outperform' rating. This positive adjustment stems from the comp…
Nov 4, 2026 Corporate Catalyst Neutral Impact 92
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Acadia Pharmaceuticals announced its third-quarter 2026 financial results, reporting total revenues of $342 million. This figure, coupled with specific mentions of strong commercia…
Nov 2, 2026 Corporate Catalyst Neutral Impact 55
AcadeMedia Releases Interim Report for Q1 2026/27
AcadeMedia AB (publ) has released its interim report for the first quarter of the 2026/27 fiscal year. This is a standard quarterly financial disclosure required for publicly liste…
Oct 13, 2026 Corporate Catalyst Bearish Impact 75
UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23
UBS analyst Ashwani Verma downgraded Acadia Pharmaceuticals (ACAD) from a 'Buy' rating to 'Neutral' and drastically cut the price target from $49 to $23. This significant revision …
Oct 8, 2026 Corporate Catalyst Bearish Impact 55
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36
RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating for Acadia Pharmaceuticals, signaling a continued belief in the company's long-term potential. However, the p…
Sep 28, 2026 Corporate Catalyst Neutral Impact 75
Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”
Acadia Pharmaceuticals received a Notice of Allowance from the USPTO for a patent related to the weight-banded dosing of trofinetide, their drug for Rett Syndrome. This is a signif…
Sep 25, 2026 Corporate Catalyst Bearish Impact 75
ACADIA Pharmaceuticals shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
This headline signals a negative corporate catalyst for ACADIA Pharmaceuticals. Analyst price target reductions often reflect concerns about future revenue, pipeline developments, …
Sep 25, 2026 Corporate Catalyst Bearish Impact 55
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citizens analyst Jason N. Butler maintained a 'Market Outperform' rating on ACADIA Pharmaceuticals but lowered the price target from $36 to $33. This action indicates that while th…
Sep 24, 2026 Corporate Catalyst Bearish Impact 85
Acadia Pharma shares are trading lower after the company announced remlifanserin narrowly missed the primary endpoint in its Phase 2 RADIANT study for Alzheimer's disease psychosis.
The failure of remlifanserin to meet its primary endpoint is a significant blow to Acadia Pharma, as this drug was a key pipeline asset with high expectations for treating Alzheime…
Sep 24, 2026 Corporate Catalyst Neutral Impact 55
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target
This 8-K filing discloses that Needham analyst Ami Fadia has reiterated a 'Buy' rating on ACADIA Pharmaceuticals (ACAD) and maintained a $41 price target. This action signals conti…
Sep 24, 2026 Corporate Catalyst Bullish Impact 85
Acadia’s Remlifanserin Advances Toward Phase 3 In Alzheimer’s Psychosis Despite Narrow Miss On Primary Endpoint
Acadia Pharmaceuticals announced Phase 2 results for remlifanserin, a drug for Alzheimer's disease psychosis. While it narrowly missed the primary endpoint (p=0.0603), it showed st…
Aug 25, 2026 Corporate Catalyst Bullish Impact 55
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Deutsche Bank analyst David Hoang maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $37 to $38. This action signals continued positive sentiment …
Aug 25, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintained an 'Equal-Weight' rating on ACADIA Pharmaceuticals while raising the price target from $27 to $28. This action reflects a slightly im…
Aug 25, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target by a modest $1, from $39 to $40. This action signals continued a…
Aug 24, 2026 Corporate Catalyst Bullish Impact 75
European Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER Study
This approval is a significant positive for Acadia Pharmaceuticals (ACAD) as it opens up the European market for DAYBU, a drug for a rare neurological disorder. The successful Phas…
Aug 17, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49
UBS analyst Ashwani Verma maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $45 to $49. This action signals continued confidence in ACADIA's futu…
Aug 12, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41
Needham analyst Ami Fadia has maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $38 to $41. This action indicates increased confidence from a pro…
Aug 10, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $35 to $39. This action signals increased confidence from a…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25
Oppenheimer analyst Matthew Hershenhorn reiterated a 'Perform' rating on ACADIA Pharmaceuticals (ACAD) but raised the price target from $23 to $25. This action signals a slightly i…
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
ACADIA Pharmaceuticals shares are trading higher after Citizens and RBC Capital raised their respective price targets on the stock.
Analyst price target increases are a significant corporate catalyst, often signaling improved sentiment and potential for stock appreciation. For ACADIA Pharmaceuticals, this sugge…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37
RBC Capital analyst Brian Abrahams maintained an 'Outperform' rating on ACADIA Pharmaceuticals and slightly raised the price target from $36 to $37. This action signals continued a…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Citizens analyst Jason N. Butler maintained a 'Market Outperform' rating on ACADIA Pharmaceuticals and slightly raised the price target from $35 to $36. This action suggests a cont…
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est
ACADIA Pharmaceuticals (ACAD) has revised its FY2026 sales guidance upwards, moving from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion. This is a positive developm…
Aug 4, 2026 Corporate Catalyst Bullish Impact 92
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate
ACADIA Pharmaceuticals announced Q2 earnings of $0.18 per share, a substantial beat over the $0.07 consensus estimate, and sales of $307.959 million, also exceeding the $295.857 mi…
Jul 21, 2026 Corporate Catalyst Bullish Impact 55
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
BMO Capital analyst Evan David Seigerman maintained an 'Outperform' rating on ACADIA Pharmaceuticals and raised the price target from $34 to $36. This action signals continued anal…
Jul 21, 2026 Corporate Catalyst Bullish Impact 55
Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
This 8-K filing discloses that Stifel analyst Paul Matteis has maintained a 'Hold' rating on ACADIA Pharmaceuticals (ACAD) while slightly increasing its price target from $24 to $2…
Jul 20, 2026 Corporate Catalyst Bullish Impact 75
Acadia Pharma Secures FDA Fast Track Designation For Remlifanserin For Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals received FDA Fast Track designation for remlifanserin, an investigational drug for Alzheimer's disease psychosis. This is a significant positive development …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.